Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales
NCT ID: NCT04383652
Last Updated: 2021-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2020-05-06
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER)
NCT04399109
SARS-CoV-2 Human Challenge Characterisation Study
NCT04865237
Collection of Anti-SARS-CoV-2 Immune Plasma
NCT04344977
SARS-COV2 Pandemic Serosurvey and Blood Sampling
NCT04334954
Respiratory Virus Sampling and Repository
NCT05266222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adult cohort
1. Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)
2. Age 16 years or older
3. Have provided informed consent
Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected.
Biological sample and clinical data collection
Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
Paediatric cohort
1. Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)
2. Age less than 16 years
3. Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected.
Biological sample and clinical data collection
Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biological sample and clinical data collection
Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Diagnosed with CoV-SARS-2 infection
2. 16 years of age or older
3. Have provided informed consent Paediatric cohort
<!-- -->
1. Diagnosed with CoV-SARS-2 infection
2. Less than 16 years of age
3. Informed consent provided by parent or caregiver
Exclusion Criteria
<!-- -->
1. 15 years of age or younger
2. Inability or unwillingness to provide informed consent or abide by the requirements of the study Paediatric cohort
<!-- -->
1. 16 years of age or older
2. Inability or unwillingness of parent or caregiver to provide informed consent or abide by the requirements of the study -
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kirby Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marianne Martinello
Role: PRINCIPAL_INVESTIGATOR
Kirby Institute, UNSW Sydney
Rowena Bull
Role: PRINCIPAL_INVESTIGATOR
School of Medical Sciences, UNSW Sydney
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NSW Health Pathology
Randwick, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Sydney Children's Hospital
Randwick, New South Wales, Australia
Blacktown Hospital
Blacktown, , Australia
Royal Prince Alfred Hospital
Camperdown, , Australia
St Vincent's Hospital
Darlinghurst, , Australia
Northern Beaches Hospital
Frenchs Forest, , Australia
Royal North Shore Hospital
Saint Leonards, , Australia
Westmead Hospital
Westmead, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VISP2005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.